Abstract:Objective To study the pharmacokinetics of the first-line anti-tuberculosis drugs including rifampicin,isoniazid,and ethambutol in a cohort of Chinese patients with tuberculosis and to determine the relationship between the pharmacokinetic parameters of these anti-tuberculosis drugs and the clinical treatment outcomes.Methods A prospective study was conducted to recruit patients diagnosed with pulmonary tuberculosis from the Inpatient Department of the Wenzhou Central Hospital from October 1,2015 to January 31,2016.A total of 72 patients were enrolled.Subjects were initially treated or retreated once,and both bacteriologically confirmed and clinically diagnosed cases were eligible.Plasma samples were collected 0.5 h before and 2 h,4 h,6 h,8 h after taking standard quadruple drugs for one week doses.Plasma concentrations were determined using LC-MS/MS.Patients were followed up 2 months after the initiation of treatment to assess the relationships between sputum negative conversion and plasma concentrations.Results Among the 72 patients,one patient was confirmed to have multidrug-resistant tuberculosis and one patient was lost to follow up.Thus,70 patients were analyzed at last,among whom 16 patients were bacteriologically negative and 54 patients were bacteriologically positive at initial diagnosis.The plasma exposures at steady state after one week of drug administration were analyzed.25.7％ (18/70) patients had a plasma peak concentration (Cmax) of rifampicin lower than the recommended range (＜8 μg/ml),38.6％ (27/70) cases had a Cmax of isoniazid lower than the recommended range (＜3 μg/ml),whereas 65.7％ (46/70) patients had a Cmax of ethambutol lower than the recommended range (＜2 μg/ml).After 2-month of treatment,among the 54 patients who were sputum bacteria positive at initial diagnosis,48 patients conversed to sputum bacteria negative,while sputum bacteria were still detected in 6 patients.The C2h,Cmax,and AUC0-8 of ethambutol were significantly higher in patients who got sputum conversion after 2-month of treatment ((1.81± 0.91) μg/ml,(1.81±0.85) μg/ml,and (7.67±3.25)μg · h · m1-1) compared with those who failed to get sputum conversion ((0.93±0.32)μg/ml,(1.06±0.25)μg/ml,and (4.93±0.72) μg · h · ml-1) (t=4.74,P＜0.01;t=4.93,P＜0.01;and t=4.95,P＜0.01,respectively).The C2 h and Cmax of isoniazid were significantly higher in patients who got sputum conversion after 2-month of treatment ((3.67±1.64) μg/ml and (3.85±1.59) μg/ml) compared with those who failed to get sputum conversion ((2.11±1.14)μg/ml and (2.11±1.14) μg/ml) (t=2.60,P=0.012;t=2.25,P=0.029,respectively).Conclusion The Cmax of drugs below the recommended reference ranges,especially isoniazid and ethambutol,were observed in some patients with pulmonary tuberculosis.The dosage of isoniazid and ethambutol may need to be modified.In addition,the sputum negative conversion after 2-month of treatment was shown to be related with the serum concentration of isoniazid and ethambutol.

Effects against Mycobacterium tuberculosis in vivo and in vitro of a Chinese tratitional drug anti-tuberculosis pill

A Clinical Study on the Infection of Multiple-Drug Resistance Pulmonary Tuberculosis and L-forms of Mycobacterium Tuberculosis

The Inhibition of Folylpolyglutamate Synthetase (folc) in the Prevention of Drug Resistance in Mycobacterium Tuberculosis by Traditional Chinese Medicine.

Study of 25-O-desacetylrifapentine Against Tubercle Bacillus Growth Activity

In Vitro Activity of Tetracycline Analogs against Multidrug-resistant and Extensive drug resistance Clinical Isolates of Mycobacterium tuberculosis

The past, present and future of tuberculosis treatment.

Randomized control study of the use of faropenem for treating patients with pulmonary tuberculosis

Bis-biguanide Dihydrochloride Inhibits Intracellular Replication of M. Tuberculosis and Controls Infection in Mice.

In Vitro and in Vivo Activities of a New Lead Compound I2906 Against Mycobacterium Tuberculosis

The Study of the Effect of the Treatment of Multi-Drug Resistent Pulmonary Tuberculosis with with Steam Inhalations and Chemotherapy

PP-003 Evaluation on the cellular immunity of M. tuberculosis in HIV/AIDS and tuberculosis co-infected individuals in China

Concomitant Resistance to Ethambutol, Isoniazid and Rifampicin in Mycobacterium Tuberculosis Isolates from China

The mechanism of Gejie Zhilao Pill in treating tuberculosis based on network pharmacology and molecular docking verification

Design, synthesis and biological evaluation of 3-substituted-2-thioxothiazolidin-4-one (rhodanine) derivatives as antitubercular agents against Mycobacterium tuberculosis protein tyrosine phosphatase B

Combination effect of azithromycin with TCM preparation Xiyanping injection against Klebsiella pneumoniae infection in rats

Effects of Bedaquiline on Antimicrobial Activity and Cytokine Secretion of Macrophages Infected with Multidrug-Resistant Mycobacterium Tuberculosis Strains

The relationship between plasma concentrations of the first-line anti-tuberculosis drugs and sputum negative conversion at early stage

Research Advance in Chinese Medicine on Anti-mycobacterium Tuberculosis

A controlled clinical study of long course chemotherapy regimens combined with immunopotentiator in the treatment of multi-drug resistant pulmonary tuberculosis

JIB-04, an inhibitor of Jumonji histone demethylase as a potent antitubercular agent against Mycobacterium tuberculosis

Plasma Concentrations of Second-Line Antituberculosis Drugs in Relation to Minimum Inhibitory Concentrations in Multidrug-Resistant Tuberculosis Patients in China: a Study Protocol of a Prospective Observational Cohort Study.